RenMab™ mice contain the entire human immunoglobulin variable domain, which streamlines discovery and eliminates the need for humanization. Our RenLite® model contains a fixed common light chain that eliminates chain mispairing during bispecific antibody development. Immunized RenMice undergo in vivo selection and affinity maturation to generate quality antibody hits.
RenMab™ mice contain the entire human immunoglobulin variable domain, which streamlines discovery and eliminates the need for humanization. Our RenLite® model contains a fixed common light chain that eliminates chain mispairing during bispecific antibody development. Immunized RenMice undergo in vivo selection and affinity maturation to generate quality antibody hits.
Models & services to get you from target to therapeutic candidate
We offer the most comprehensive collection of humanized models to evaluate efficacy of human immunotherapies.
From point mutation knock-in alleles to transgenics, we deliver quality custom animal and cell models.
Comprehensive preclinical PK/PD, in vivo, and in vitro evaluation of novel test articles.
Industry-leading technologies that accelerate drug discovery
From design to F1 in 5-7 months, our proprietary platform delivers quality models faster.
Our suite of best-in-class fully human antibody mice de-risk your therapeutic antibody discovery.
Antibodies derived from RenLite mice against 200+ TAA targets are available for BsADC generation.
KO RenMice provide a solution for challenging GPCR targets with complex multi-pass transmembrane structure.
HLA/RenMab mice generate antibodies against intracellular TAAs with high specificity to the target pHLA complex.
RenNano-derived antibodies can infiltrate tumor tissues, cross the blood-brain barrier, or be constructed into other therapies.
Why Waltham, MA? Because we want to get closer to our clients!
Our priority? Your project success. Every detail matters to us. Explore the next level of collaboration and excellence. Welcome to the future of innovation!
News & Events
Powered by cutting-edge gene editing technologies and a state-of-the-art animal facility, Biocytogen offers solutions for preclinical antibody drug discovery and efficacy validation. Our CRO & vivarium sites in Boston and China have enabled global partnerships with numerous academic and industrial clients to accelerate basic and preclinical research.
Founded in 2009, our proprietary, efficient genetic engineering technologies have made us a global leader in animal and cell model generation. Development of our advanced chromosome engineering technology and high-throughput antibody discovery platform further expanded our capabilities for therapeutic antibody discovery using our fully human antibody mice.
With the largest catalog of humanized models available and an experienced in vivo pharmacology team, we have completed over 1,300 drug evaluation projects. Our fast turnaround times and dedication to superior customer service have set us apart.
Whether you need gene editing, antibody discovery, or pharmacology services, our cutting-edge platforms provide fast and reliable solutions.
Biocytogen provides hundreds of genetically modified off-the-shelf BIOMICE for basic and preclinical research. Our large collection of humanized immune-checkpoint, humanized cytokine/cytokine receptor, humanized TAA mice, and immunodeficient mice, which have been published in hundreds of studies, facilitate in vivo efficacy assessments of novel anti-human immunotherapies.
